...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Novel approaches to targeting BRD4

"Novel approaches to targeting BRD4" authored by Zenith's Olesya A.Kharenko and Henrik C.Hansen was published earlier this year in Drug Discovery Today: Technologies. It is a review focusing on recent advances in the use of alternatives to reversible BET inhibitors: 1) Strategies/drugs that promote BRD4 protein degradation; and 2) Irreversible small-molecule inhibitors of BRD4

https://www.ncbi.nlm.nih.gov/pubmed/29233295

https://www.sciencedirect.com/science/article/pii/S1740674916300427

Share
New Message
Please login to post a reply